Plasma Fractionation Market by Product (Coagulation Factor Concentrates, Immunoglobulin, Protease Inhibitors and Albumin), Application (Immunology, Neurology, Critical Care, Hematology and Pulmonary), End users (Hospitals, Clinical Research Laboratories and Academic Institutions) – Analysis & Forecast 2019-2030

Report ID : 166  |  Published Date : May 2020  |  Pages : 160  |  Region : Global  |  Report Code : PH-10

Plasma Fractionation Market Overview and Introduction

Plasma fractionation is a general process of separating various components of blood plasma. Plasma fractionation was developed by Cohn and is carried out at low temperatures by the addition of ethanol in 8% to 40% V/V at the end, for albumin separation. Nowadays, plasma fractionation can also be carried out with the combination of chromatographic techniques to achieve higher quality and yield. Plasma fractionation is used for the treatment of immunological disorders, protein deficiency and several other medical applications.

The growth of the plasma fractionation market can be attributed to a wide range of therapeutic applications of this technique, increasing prevalence of auto-immune disorders, increasing number of hemophilic patients, rising prevalence of respiratory disorders, and increasing generic population among others. Proteins present in plasma have several therapeutic applications, similarly, plasma-derived proteins can also be used as a biomarker in the diagnosis of diseases. However, high costs, stringent government regulations, and limited reimbursement are anticipated to restrain the growth of the market.

The plasma fractionation market is segmented by product type, application, end-users, and region.

Plasma Fractionation Market By Product

Based on product, the plasma fractionation market is segmented into coagulation factor concentrates, immunoglobulin, protease inhibitors, albumin, and other plasma-derived products. Coagulation factor concentrates can be further segmented into factor VII, factor IX, factor VII, prothrombin coagulation concentrates, Von Willebrand factors, and fibrinogen concentrates. Whereas, immunoglobulin can be further segmented into subcutaneous immunoglobulin and intravenous immunoglobulin. Based on product, the immunoglobulin market is expected to account for the largest market share during the forecast period. 

Plasma Fractionation Market By Application

Based on application, the plasma fractionation market is segmented into immunology, neurology, critical care, hematology, and pulmonary. Neurology and hematology are expected to account for the largest market share during the forecast period owing to rising incidences of neurological disorders and the increasing number of anemic patients globally. 

Plasma Fractionation Market By End User

Based on end user, the plasma fractionation market is segmented into hospitals, clinical research laboratories, and academic institutions. Hospitals is anticipated dominate the plasma fractionation market in 2019.

Plasma Fractionation Market by Region

The plasma fractionation market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America accounted for the largest market share in 2019, owing to the rising number of hemophilic patients, increasing use of immunoglobulin for therapeutics application, rising prevalence of respiratory diseases, and increasing generic population. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period owing to the increasing aging population, and increasing prevalence of hemophilic patients in this region.

Plasma Fractionation Market Prominent Players

Some prominent players in the plasma fractionation market include Octapharma AG, CSL Ltd., China Biologics Products Holdings, Inc., Baxter International Inc., Kendrion, Biotest, Shanghai RAAS blood products Co., Ltd., GRIFOLs, Takeda Biopharmaceuticals, and Bio Products Laboratory, among others.